Kyowa sells U.S. rights to cancer drug delivery patch
To view this email as a web page, click here

Today's Rundown

Featured Story

J&J, following in Sanofi's footsteps, tasks i2o with oral delivery of large molecules

Big Pharma’s embrace of i2o Therapeutics continues. After signing up Sanofi last year, the spinout from Harvard University has started 2022 by disclosing a deal to work with Johnson & Johnson on oral delivery of macromolecules.  

read more

Top Stories

2seventy brings in Genevant delivery tech for Novo Nordisk in vivo gene editing project

Bluebird bio’s oncology spinoff has secured rights to a lipid nanoparticle delivery technology from Genevant Sciences. The spinoff, 2seventy bio, will use the delivery technology in an in vivo gene editing collaboration with Novo Nordisk.

read more

Kyowa sells U.S. rights to cancer drug delivery patch to Cumberland

Kyowa Kirin has sold its FDA-approved oncology patch to Cumberland Pharmaceuticals. The deal will give Cumberland the U.S. rights to Sancuso, a product that delivers a drug through the skin to stop nausea, in return for $13.5 million upfront plus milestones and royalties.

read more

Selecta taps Ginkgo to create better capsids for gene therapy delivery 

Selecta Biosciences and Ginkgo Bioworks are extending their alliance to cover gene therapy delivery. Just months after disclosing a rare disease pact, the partners have unwrapped a second deal focused on the development of gene therapy capsids that address the limitations of current delivery vehicles.

read more

Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts

On the same day in December, Teva and Sandoz launched copycat versions of Emergent's opioid overdose nasal spray Narcan, suggesting its reign of dominance was soon to end. But don’t write off the branded treatment just yet, analysts at Cantor Fitzgerald say, citing "market complexities."

read more

Resources

Whitepaper: Tailored, Dedicated Support Expedites COVID-19 Vaccine Trial

Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference.

Research: How Buffer Prep Services Alleviate Sudden Spikes in Campaign Volume

Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific

Whitepaper: QC for ex vivo manipulated cell lines and tissues

A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants.

Webinar: Using Next Best to Elevate your Omnichannel Marketing Strategy

Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events